Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adverum Biotechnologies

4.61
+0.11002.44%
Post-market: 4.610.00000.00%18:38 EDT
Volume:80.11K
Turnover:367.82K
Market Cap:95.90M
PE:-0.84
High:4.67
Open:4.51
Low:4.49
Close:4.50
Loading ...

Adverum Biotechnologies Q3 2024 GAAP EPS $(1.30) Beats $(1.31) Estimate

Benzinga
·
05 Nov 2024

Adverum Biotechnologies Inc: on Track to Initiate Pivotal Program in 1H 2025

THOMSON REUTERS
·
05 Nov 2024

Adverum Biotechnologies Inc: Appointed Jason Mitchell as Chief Commercial Officer

THOMSON REUTERS
·
05 Nov 2024

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

GlobeNewswire
·
05 Nov 2024

Oppenheimer Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)

TIPRANKS
·
17 Oct 2024

BRIEF-Adverum Biotechnologies Appoints Jason L. Mitchell As Chief Commercial Officer As It Prepares To Initiate Pivotal Program

Reuters
·
16 Oct 2024

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program

THOMSON REUTERS
·
16 Oct 2024

Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Dow Jones
·
16 Oct 2024

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks
·
12 Oct 2024

Adverum Biotechnologies participates in a conference call with Oppenheimer

TIPRANKS
·
08 Oct 2024

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Zacks
·
03 Oct 2024

Bet on 5 Top-Ranked Stocks With Rising P/E

Zacks
·
02 Oct 2024

Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)

TIPRANKS
·
27 Sep 2024

Truist Financial Issues a Buy Rating on Adverum Biotechnologies (ADVM)

TIPRANKS
·
20 Sep 2024